AWA
BMRN icon

Arkadios Wealth Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Arkadios Wealth Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-148
Closed -$11K – 1947
2021
Q1 		$11K Buy
+148
New +$12.1K ﹤0.01% 1148
2020
Q3 		– Sell
-38
Closed -$4.8K – 1030
2020
Q2 		$4.8K Buy
+38
New +$3.78K ﹤0.01% 787

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Arkadios Wealth Advisors's BMRN Position: Q2 2021 in Review

Arkadios Wealth Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2021, closing a stake of 148 shares — an estimated $11K sold.

Arkadios Wealth Advisors first reported a position in BMRN in Q2 2020 and held it in 2 quarters. The position peaked at $11K in Q1 2021. 529 funds tracked by Wall St. Rank hold BMRN as of Q2 2021.

  • Arkadios Wealth Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Arkadios Wealth Advisors sold 148 BioMarin Pharmaceuticals shares in Q2 2021, an estimated $11K.
  • Arkadios Wealth Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2020 and held it in 2 quarters.
  • Arkadios Wealth Advisors's BioMarin Pharmaceuticals position peaked at $11K in Q1 2021.
  • 529 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2021.

Based on Arkadios Wealth Advisors's 13F filing for Q2 2021, filed 28 Jul 2021.